September 30, 2022
2 min watch
Save
VIDEO: Visus acquires assets from ViewPoint Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video from Eyecelerator@AAO, Visus Therapeutics CEO Ben Bergo discusses the company’s acquisition of ViewPoint’s patents and how this will help it further develop treatment options for presbyopia and cataracts.
“By this acquisition, we now have a library of compounds to again develop an aggregation inhibitor to address this cataract that can develop, but also presbyopia,” Bergo said.
Published by:
Sources/Disclosures
Collapse
Source:
Bergo B. Visus Therapeutics. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Bergo reports being the CEO of Visus Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.